Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.66 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.52 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2018558 | 1.00 | KCNH2 (0.66) | KCNH2ADRB2ADRB1ADRB3SLC6A2 | |
| SCHEMBL2018559 | 1.00 | KCNH2 (0.66) | KCNH2ADRB2ADRB1ADRB3SLC6A2 | |
| SCHEMBL2026331 | 0.86 | KCNH2 (0.66) | KCNH2ADRB2ADRB1ADRB3SLC6A2 | |
| SCHEMBL2026333 | 0.86 | KCNH2 (0.66) | KCNH2ADRB2ADRB1ADRB3SLC6A2 | |
| SCHEMBL2026335 | 0.86 | KCNH2 (0.66) | KCNH2ADRB2ADRB1ADRB3SLC6A2 | |
| SCHEMBL2020023 | 0.81 | KCNH2 (0.78) | KCNH2ADRB2ADRB1ADRB3SLC6A2 | |
| SCHEMBL2020027 | 0.81 | KCNH2 (0.78) | KCNH2ADRB2ADRB1ADRB3SLC6A2 | |
| SCHEMBL2020025 | 0.81 | KCNH2 (0.78) | KCNH2ADRB2ADRB1ADRB3SLC6A2 | |
| SCHEMBL14864482 | 0.79 | KCNH2 (0.41) | KCNH2ADRB3 | |
| SCHEMBL11251345 | 0.73 | ADRB2 (0.71) | KCNH2ADRB2ADRB1ADRB3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079852-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140031363-A1 | NMDA Receptor Antagonists for Neuroprotection | LIOTTA DENNIS C (US) | 2014-01-30 | — | — | US | disclosed |
| US-8420680-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2013-04-16 | — | — | US | disclosed |
| US-20110160223-A1 | NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders | EMORY UNIVERSITY | 2011-06-30 | — | — | US | disclosed |
| US-20090253710-A1 | NMDA Receptor Antagonists for Neuroprotection | EMORY UNIVERSITY | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253710-A1 | NMDA Receptor Antagonists for Neuroprotection | GRIN1, GRIN2C, GRIK1 | KCNH2 137/4885ADRB2 509/4885ADRB1 388/4885 |
| US-20110160223-A1 | NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders | GRIN2A, GRIN2B, GRIN1 | KCNH2 469/4885ADRB2 418/4885ADRB1 498/4885 |
| US-20140031363-A1 | NMDA Receptor Antagonists for Neuroprotection | GRIN1, GRIN2C, GRIK1 | KCNH2 135/4885ADRB2 501/4885ADRB1 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.